Abstract 5408: Liposomal doxorubicin with modified EGCG increased antitumor activity by topical targeting efficiency into tumor
Authors: Sugiyama Ikumi , Kaihatsu Kunihiro , Kato Nobuo , Sadzuka Yasuyuki 
Published: May 2015

Purpose: The aim of this study is increase of antitumor activity

using novel liposome with (-)-epigallocatechin-3-gallate (EGCG) as one of the green tea components. Liposome has been known as a one of useful drug carriers for delivering drug into targeting site. Moreover, some ligand is able to modify around liposomal membrane by a simple method. On the other hand, it was reported that surface of high grade tumor cell expresses 67kDa laminin receptor (67LR) which intermediates of cytostatic effect of EGCG, and EGCG is able to induce apoptosis selectively. Our strategy was to prepare liposomal doxorubicin with EGCG as carrier ligand for getting antitumor activity by both apoptosis and doxorubicin at tumor site. In this study, we tried to prepare EGCG-modified liposome and evaluated the antitumor activity in vitro.

Methods: The liposomal doxorubicin was prepared by L-α-distearoylphosphatidylcholine, cholesterol, L-α-distearoylphosphatidyl-DL-glycerol and doxorubicin (100:100:60:18 μmol). Doxorubicin included EGCG-modified liposome (EL-DOX) was prepared to add EGCG-dipalmitate. Amount of EGCG modification on liposomal membrane was

determined using DPPH assay. On P388 leukemia cells and M5076 ovarian sarcoma cells, cytotoxicity was evaluated by WST-8 assay and shown IC50. DOX uptake into tumor cells was evaluated in vitro. The concentration of doxorubicin into tumor cells was determined with a fluorescence spectrophotometer at an excitation wavelength of 500 nm and an emission wavelength of 550 nm.

Results and Discussion: Particle sizes of EL-DOX were 147 nm on average, zeta potential was -33.1 mV and encapsulated ratio of doxorubicin was 96.5 %. These data of sizes and zeta potentials were better for intravenous administration of liposomes. EGCG ratio on liposomal membrane (71.0 %) was enough to show its ability. In the study of doxorubicin uptake into tumor cells, EL-DOX group was increased amount of doxorubicin for 30 min. The doxorubicin level of EL-DOX was significantly higher compared with that of unmodified liposomal doxorubicin (p&lt;0.05). At cytotoxicity, EL-DOX was stronger than unmodified liposomal doxorubicin. It was provided that IC50 of EL-DOX was also 125 times higher than EGCG solution which was reported to have been antitumor activity. Furthermore, co-incubation of EGCG solution and liposomal doxorubicin was not shown the enhancement effect both doxorubicin uptake into cells and the cytotoxicity. It was suggested that superior effect were shown in modification of EGCG around liposomal membrane, not mixture of EGCG and liposome. In conclusion, EL-DOX exhibited strong antitumor activity efficiently.

Citation Format: Ikumi Sugiyama, Kunihiro Kaihatsu, Nobuo Kato, Yasuyuki Sadzuka. Liposomal doxorubicin with modified EGCG increased antitumor activity by topical targeting efficiency into tumor. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5408. doi:10.1158/1538-7445.AM2014-5408